5 Key Takeaways

• 1

  Many MSC therapy programs struggle to progress beyond early clinical stages due to donor-to-donor variability affecting efficacy.

• 2

  The choice of cell culture system significantly impacts the scalability of MSC therapies, influencing development and manufacturing processes.

• 3

  Teams often realize their MSC processes won't scale during the first true scale-up, when changes in cell biology become evident.

• 4

  Understanding cost of goods (COGS) is crucial, as early decisions can lock in cost structures that complicate later manufacturing.

• 5

  Future advancements in MSC therapies will likely involve standardized, automated systems and improved logistics for better scalability.